Eisai Co., Ltd. (ESAIY) Stock

About Eisai Co., Ltd.

Eisai Co., Ltd. is a Japanese pharmaceutical firm deeply involved in the entire lifecycle of drug development, from initial research and innovation to manufacturing, distribution, and international trade within Japan. Its comprehensive product portfolio includes prominent medications such as Dayvigo, prescribed for insomnia, and the potent anticancer drug Lenvima, a molecularly targeted therapy effective against thyroid cancer, hepatocellular carcinoma, and renal cell carcinoma when paired with everolimus. The company also markets Methycobal for peripheral neuropathy and Halaven, another anticancer agent targeting breast cancer. Further offerings encompass Jyseleca, a janus kinase inhibitor; Elental, a branched-chain amino acid formulation; Goofice and Movicol, utilized for managing chronic constipation; Fycompa, an antiepileptic; Pariet, a proton-pump inhibitor; and Aricept, a treatment for Alzheimer's and Dementia with Lewy bodies. Additionally, it produces Chocola BB plus, a vitamin B2 supplement. Eisai maintains a strategic alliance with Bristol Myers Squibb, focusing on the joint development and commercialization of the antibody drug conjugate, farletuzumab ecteribulin. Established in Tokyo, Japan, in 1941, the company was initially known as Nihon Eisai Co., Ltd. before adopting its current name, Eisai Co., Ltd., in 1955.

Eisai Co., Ltd. is headquartered in JP.

Eisai Co., Ltd. (ESAIY) stock trades at $6.93 with a market capitalization of $7.82B. The stock is valued at a price-to-earnings (P/E) ratio of 33.27, price-to-book of 1.43, price-to-sales of 1.56. Over the past 52 weeks the stock has ranged between $5.69 and $9.22, and currently trades 24.8% below its 52-week high. It pays a dividend yielding 2.89%.

On profitability, Eisai Co., Ltd. generates a return on equity (ROE) of 4.44%, return on capital employed of 3.63%, an operating margin of 4.87%, a net profit margin of 4.67%.

Official website: www.eisai.com